Maricann Group (CNSX:MARI – Get Free Report) had its price target boosted by National Bankshares from $13.25 to $15.00 in a research report issued to clients and investors on Thursday,BayStreet.CA reports.
Separately, Royal Bank Of Canada raised their price target on shares of Maricann Group from $6.00 to $16.00 in a research note on Wednesday, December 10th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Maricann Group currently has a consensus rating of “Buy” and an average price target of $14.10.
Check Out Our Latest Report on MARI
Maricann Group Stock Performance
About Maricann Group
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients. The Company is undertaking an expansion of the cultivation and support facilities to support existing and future patient growth.
Further Reading
- Five stocks we like better than Maricann Group
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
